001), 304 (170) (P < .001), 534 (189) (P < .001), and 254 (191) (P < .003), respectively.

Conclusions: This study suggests that pregnancy may partially deplete CD4 cells because a significant difference was observed in mean (SD) CD4 cell count in HIV-seropositive

and HIV-seronegative pregnant women at various gestational ages. Chronological age did not affect the mean CD4 cell count if there was no accompanying disease condition. We also conclude that PCV in HIV-seropositive pregnant women was directly proportional to their Selleck Caspase inhibitor CD4 cell counts.”
“Aim: To investigate the incidence, causes and delivery methods of iatrogenic preterm births.

Material & Methods: A retrospective study was conducted to review a cohort of preterm birth records to learn the incidence,

causes and delivery methods of 828 iatrogenic preterm births from January 2004 to June 2007. The chi-squared and two tailed Student’s t-test were used for statistical analysis.

Results: During the 3.5-year study period, the total incidence of iatrogenic preterm birth was 6.4%, accounting for 49.8% of the total recorded preterm births. Specifically, the proportion of iatrogenic preterm births to the total recorded preterm births in 2005 was 51.9%, the highest during the study. The top three etiologies of iatrogenic preterm birth were intrahepatic cholestasis of pregnancy, hemorrhage and hypertensive disorder complicating

pregnancy. Among the preterm births studied, 62 pregnancies delivered prior to term were for no recorded indications. Seven hundred and twenty-nine iatrogenic QNZ in vivo preterm births underwent cesarean section.

Conclusions: Iatrogenic preterm birth has become the main reason for preterm births and no recorded indications have become one cause of it. Cesarean delivery was the main delivery method among iatrogenic preterm births. Obstetricians should choose the delivery method strictly.”
“Background and Objectives

Transfusion-related acute lung injury (TRALI) prevention strategies in platelet (PLT) apheresis donors focus on identifying antileucocyte antibody-positive donors. The use of microbead based assays MAPK inhibitor for screening purposes is hampered by the lack of a consensus cut-off for TRALI prevention and the undefined role of anti-leucocyte antibodies in never-alloexposed donors. This study evaluated anti-leucocyte antibody assays in PLT apheresis donors with and without prior immunizing events with special focus on microbead assay cut-offs, antibody specificities and their potential significance in never-alloexposed donors.

Material and Methods

Blood samples of male and female PLT apheresis donors with and without history of prior immunization were tested for anti-leucocyte antibodies.

Results

Of 262 female and 118 male PLT apheresis donors, 37 center dot 4% had prior immunizing events.